Pier Capital, LLC Intra Cellular Therapies, Inc. Transaction History

Pier Capital, LLC

$714 Million
Q1 2024

A detailed history of Pier Capital, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Pier Capital, LLC holds 54,454 shares of ITCI stock, worth $4.03 Million. This represents 0.53% of its overall portfolio holdings.

Number of Shares

54,454

Previous 55,050 1.08%

Holding current value

$4.03 Million

Previous $3.94 Million 4.41%

% of portfolio

0.53%

Previous 0.57%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	SELL	$64.37 - $75.65 $38,364 - $45,087	-596 Reduced 1.08%	54,454 $3.77 Million
Q4 2023 Feb 15, 2024	SELL	$46.37 - $73.65 $4.36 Million - $6.93 Million	-94,079 Reduced 63.09%	55,050 $3.94 Million
Q3 2023 Nov 14, 2023	SELL	$52.09 - $64.1 $86,677 - $106,662	-1,664 Reduced 1.1%	149,129 $7.77 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $158,378 - $192,476	2,897 Added 1.96%	150,793 $9.55 Million
Q1 2023 May 10, 2023	BUY	$43.8 - $56.99 $225,788 - $293,783	5,155 Added 3.61%	147,896 $8.01 Million

Q4 2022 Feb 15, 2023	SELL	$44.07 - $54.45 $57,158 - $70,621	-1,297 Reduced 0.9%	142,741 $7.55 Million
Q3 2022 Nov 15, 2022	BUY	$42.7 - $59.99 $1.17 Million - $1.64 Million	27,392 Added 23.48%	144,038 $6.7 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $5.02 Million - $7.66 Million	116,646 New	116,646 $6.66 Million
Q1 2021 May 13, 2021	SELL	$30.8 - $39.51 $5.88 Million - $7.54 Million	-190,833 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$23.34 - $32.22 $4.45 Million - $6.15 Million	190,833 New	190,833 $6.07 Million

Others Institutions Holding ITCI

# of Institutions

382

Shares Held

77.7M

Call Options Held

1.7M

Put Options Held

1.13M

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $6.99B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pier Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pier Capital, LLC with notifications on news.

Account